One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Bone Morphogenetic Protein Market

[ 英語タイトル ] Bone Morphogenetic Protein Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083606
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 115
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Johnson & Johnson
- Ember therapeutics Inc.
- Integra Lifesciences Holdings Corporation
- Medtronic PLC
- Bio-Techne (R&D Systems, Inc.)
- Merck KGaA
- Pfizer, Inc.
- Stryker Corporation
- Thermo Fischer Scientific
- Zimmer Biomet Holdings, Inc.

[Report Description]

The global bone morphogenetic protein market is expected to grow with a CAGR of 2.5% during the forecasted period. The key factors that are responsible for the growth of the market include the growth in the incidences of sports-related injuries, the growing demand for minimally invasive surgeries, and technological advancements that are being done in the field of the bone morphogenetic protein.

According to the Centre for Disease Control and Prevention, the number of people participating in sports is increasing across both developing and developed nations, and this is ultimately leading to an increased number of sports injuries. Approximately, 8.6 million individuals are getting injured during sports annually, as stated by the National Institute of Health (NIH), 2016. This accounts for 34.1 people per 1,000. Spinal injury is the most frequent injury that was seen among the injured population during NIH survey.

As the number of such sports-related injury is increasing, there is a growing demand for bone morphogenetic protein, as this protein helps people who need to obtain bone formation.

Key Market Trends

Spinal Fusion is Expected to Hold the Highest Market Share in the Application Segment

In the application segment, spinal fusion is believed to have the largest market size. Bone morphogenetic protein (BMP) is a protein which stimulates the formation of bone in the body and it is widely used in the spinal fusion surgery. Studies have revealed that BMP is accepted widely to facilitate the fusion at the rate greater than that of traditional bone graft surgery. Due to this reason, BMP gives the surgeon the freedom to perform the surgery with the ease of the improved fusion rate, which avoids the complications of an iliac crest autograft (hip) graft harvest. When the hip graft is avoided, it shortens the amount of the time taken for surgery, and reduces complication rates, allowing for quicker and less painful recovery time. With the rise in the number of spinal surgeries and the ease of surgery with the help of BMP, its application is increasing rapidly in spinal fusion surgery.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America currently dominates the market and is expected to continue its stronghold for a few more years. A well-established healthcare system and the adoption of novel technologies in the region are the prime factors responsible for the growth of the market in this region.

The US FDA approved the protein molecule called rhBMP-2 has become one of the preferred procedure for the surgeries associated with bone in the United States. As per the data published by National Spinal Cord Injury Statistical Center, 2019, approximately 17,730 cases of spinal cord injuries occur annually in the United States, which indicates that there is a great scope for the bone morphogenetic protein usage in the country.

Competitive Landscape

The market is moderately competitive and consists of several companies. In terms of market share, a small number of major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products at affordable prices. Companies like Medtronic Inc., Stryker Corporation, Thermo Fischer Scientific hold a substantial market share.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Incidences of Sports-related Injury
4.2.2 Rising Demand for Minimally Invasive Surgeries
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 High Cost of Procedure
4.3.2 Alternative Treatment Availability
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Type
5.1.1 Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2
5.1.2 Recombinant Human Bone Morphogenetic Protein (rhBMP) -7
5.2 Application
5.2.1 Spinal Fusion
5.2.2 Trauma
5.2.3 Reconstructive Surgery
5.2.4 Oral-maxillofacial
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Johnson & Johnson
6.1.2 Ember therapeutics Inc.
6.1.3 Integra Lifesciences Holdings Corporation
6.1.4 Medtronic PLC
6.1.5 Bio-Techne (R&D Systems, Inc.)
6.1.6 Merck KGaA
6.1.7 Pfizer, Inc.
6.1.8 Stryker Corporation
6.1.9 Thermo Fischer Scientific
6.1.10 Zimmer Biomet Holdings, Inc.




Recommended reports